They all sound great, and I hope you are right about the grant. But to add to your post.
1. The grant we have applied for has had funding increase from 3-4 recipients to 20. So far 8 grants under UG3/UH3 have received funding.
That’s great, so we have 12 potential awardees to go. What is the pool size of the applicants? 2? 4? 60? And do we know how BICX sizes up with them? 27 isn’t exactly a competitive number unless you’re comparing it to, say, 40, then I guess.
2. Biocorrx has a confidentiality agreement with NIDA and NIAA - They want to work with us.
You mean the NIDA that only agreed to be an “observer” at the meeting. Doesn’t seem to be a robust and hands-on participant. They agreed to observe. That is all.
3. NIDA attended our pre-IND meeting - They want to work with us.
See #2.
4. None of the applications in our group have been listed as funded yet so everyone is still waiting - see link below with my instructions.
This really doesn’t tell us anything. Again, what is the pool size and how do BICX compare? What if the competitors’ impact score is 15 and below? I would not be surprised if BICX has already received an email stating the grant was rejected, and are now preparing another PR to fluff the stock before it plummets....even further.
5. We received a “likely to be funded score” of 27.
Likely compared to scores above 40, sure, but again, what is the percentile? The NIH automatically issues just-in-time emails to ALL applications that receive an overall impact score of 30 or less. Automatically. To all. 30 or less. The NIH website actually states that if a company’s percentile is well beyond their payline then basicaly don’t bother submitting any additional paperwork..... even if they DID receive a just in time email. It’s on their website. Granier is not going to say this, of course.
6. We are in a opioid crisis - they are asking for solutions, we are one. The articles being passed around about good scores not being funded are talking about different agencies not battling a crisis with increased funding.
I agree that there is increased demand for treatment options within this sector, but BICX is not the only company fighting this, and frankly, a score of 27 tells me that their solutions are not too impressive with the NIH panel. Just a mere 3 more points and BICX wouldn’t even have recieved that email.
I’m not saying there’s absolutely zero chance of BICX getting this grant. I’m just not convinced that the chances are as high, and judging by the stock price, I’m not the only one.